These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 34054867)

  • 1. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.
    Tu S; Lin X; Qiu J; Zhou J; Wang H; Hu S; Yao Y; Wang Y; Deng Y; Zhou Y; Shao A
    Front Immunol; 2021; 12():650105. PubMed ID: 34394072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
    Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
    ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Advances in Immunotherapy for Glioblastoma.
    Mende AL; Schulte JD; Okada H; Clarke JL
    Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GBM immunotherapy: Exploring molecular and clinical frontiers.
    Ghosh MK; Kumar S; Begam S; Ghosh S; Basu M
    Life Sci; 2024 Nov; 356():123018. PubMed ID: 39214286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current approaches in glioblastoma multiforme immunotherapy.
    Aghajani M; Jalilzadeh N; Aghebati-Maleki A; Yari A; Tabnak P; Mardi A; Saeedi H; Aghebati-Maleki L; Baradaran B
    Clin Transl Oncol; 2024 Jul; 26(7):1584-1612. PubMed ID: 38512448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: The State-of-Art in Immuno-Oncology, What to Do With Glioblastoma?
    Cui X; Wang Q; Kang C
    Front Immunol; 2021; 12():788733. PubMed ID: 34777399
    [No Abstract]   [Full Text] [Related]  

  • 11. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
    Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic vaccination for glioblastoma].
    Dietrich PY; Dutoit V
    Med Sci (Paris); 2020 Apr; 36(4):319-322. PubMed ID: 32356704
    [No Abstract]   [Full Text] [Related]  

  • 13. Harnessing the immune system in glioblastoma.
    Brown NF; Carter TJ; Ottaviani D; Mulholland P
    Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Salinas RD; Durgin JS; O'Rourke DM
    CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade.
    Li T; Xu D; Ruan Z; Zhou J; Sun W; Rao B; Xu H
    Adv Sci (Weinh); 2024 May; 11(18):e2310163. PubMed ID: 38460167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges.
    Lu J; Huo W; Ma Y; Wang X; Yu J
    Cancer Lett; 2024 Sep; 600():217185. PubMed ID: 39142498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy.
    Ishikawa E; Miyazaki T; Takano S; Akutsu H
    Brain Tumor Pathol; 2021 Jul; 38(3):149-155. PubMed ID: 33977360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
    Genoud V; Migliorini D
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scientometric analysis of immunotherapies for gliomas: Focus on GBM.
    Xing Y; Yasinjan F; Geng H; He M; Yang M; Gao Y; Zhang J; Zhang L; Guo B
    Asian J Surg; 2024 Oct; 47(10):4271-4280. PubMed ID: 38448290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.